Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CMMBNASDAQ:HOOKNASDAQ:IMNMNASDAQ:NXTCNASDAQ:ONCT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$0.66-1.6%$0.73$0.42▼$1.89$7.28M0.36190,684 shs11,541 shsHOOKHookipa Pharma$0.81-5.2%$0.74$0.41▼$2.05$79.76M1.02713,132 shs1.84 million shsIMNMImmunome$14.26-0.1%$22.41$4.44▼$30.96$851.18M1.66725,369 shs736,054 shsNXTCNextCure$1.29-10.4%$1.74$0.98▼$2.57$35.99M0.4233,437 shs156,328 shsONCTOncternal Therapeutics$8.25-3.5%$8.85$5.57▼$13.14$22.19M1.2611,923 shs6,862 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics0.00%+13.56%-7.84%+33.44%-56.77%HOOKHookipa Pharma+11.11%+11.48%+20.98%+19.72%-10.62%IMNMImmunome-2.66%-17.89%-40.54%-12.99%+157.12%NXTCNextCure-5.88%-4.64%-27.64%+21.01%-5.26%ONCTOncternal Therapeutics-1.77%-1.15%+4.87%-4.01%+32.46%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMMBChemomab Therapeutics2.076 of 5 stars3.35.00.00.00.01.70.6HOOKHookipa Pharma3.2052 of 5 stars3.53.00.00.03.71.71.3IMNMImmunome1.5197 of 5 stars3.50.00.00.02.61.70.0NXTCNextCure4.3125 of 5 stars3.55.00.04.60.01.71.3ONCTOncternal Therapeutics2.4305 of 5 stars3.33.00.00.01.91.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics2.67Moderate Buy$7.00962.22% UpsideHOOKHookipa Pharma3.00Buy$5.17540.95% UpsideIMNMImmunome3.00Buy$32.67129.08% UpsideNXTCNextCure3.00Buy$6.00365.12% UpsideONCTOncternal Therapeutics2.67Moderate Buy$31.33279.80% UpsideCurrent Analyst RatingsLatest NXTC, ONCT, IMNM, CMMB, and HOOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/15/2024ONCTOncternal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.004/1/2024IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $33.003/25/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.003/25/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.503/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.001/30/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.001/29/2024IMNMImmunomeLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/29/2024IMNMImmunomeSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.001/29/2024ONCTOncternal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AHOOKHookipa Pharma$20.13M3.96N/AN/A$0.91 per share0.89IMNMImmunome$14.02M60.71N/AN/A$2.77 per share5.15NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/AONCTOncternal Therapeutics$790K28.09N/AN/A$10.19 per share0.81Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$24.22M-$2.12N/AN/AN/AN/A-114.00%-88.53%5/9/2024 (Confirmed)HOOKHookipa Pharma-$81.58M-$0.88N/AN/AN/A-405.28%-72.30%-40.51%5/9/2024 (Estimated)IMNMImmunome-$106.81M-$5.39N/AN/AN/A-761.92%-69.74%-31.40%5/3/2024 (Estimated)NXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)ONCTOncternal Therapeutics-$39.48M-$13.51N/AN/AN/A-5,029.17%-95.87%-83.56%5/2/2024 (Estimated)Latest NXTC, ONCT, IMNM, CMMB, and HOOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/ACMMBChemomab Therapeutics-$0.20N/A+$0.20N/AN/AN/A3/28/2024Q4 2023IMNMImmunome-$0.28-$0.54-$0.26$3.14$3.40 million$3.83 million3/22/2024Q4 2023HOOKHookipa Pharma-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/A3/7/202412/31/2023CMMBChemomab Therapeutics-$0.40-$0.26+$0.14-$0.26N/AN/A 3/7/2024Q4 2023ONCTOncternal Therapeutics-$3.09-$3.11-$0.02-$3.11$0.17 million$0.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/AHOOKHookipa PharmaN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A4.324.32HOOKHookipa PharmaN/A3.503.50IMNMImmunomeN/A6.636.63NXTCNextCureN/A16.3816.38ONCTOncternal TherapeuticsN/A6.946.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%HOOKHookipa Pharma63.88%IMNMImmunome44.58%NXTCNextCure42.65%ONCTOncternal Therapeutics16.05%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%HOOKHookipa Pharma5.82%IMNMImmunome20.00%NXTCNextCure11.90%ONCTOncternal Therapeutics8.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics2011.05 million9.73 millionNot OptionableHOOKHookipa Pharma5698.95 million93.19 millionOptionableIMNMImmunome5559.69 million47.76 millionOptionableNXTCNextCure8227.90 million24.58 millionOptionableONCTOncternal Therapeutics272.69 million2.47 millionOptionableNXTC, ONCT, IMNM, CMMB, and HOOK HeadlinesSourceHeadlineOncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Releasezacks.com - April 25 at 11:05 AMStockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)americanbankingnews.com - April 25 at 2:52 AMAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)markets.businessinsider.com - April 23 at 6:53 PMEwing Sarcoma Drug Pipeline Market Research 2024: Insights About 25+ Companies and 25+ Pipeline Drugsuk.finance.yahoo.com - April 19 at 3:28 PMOncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancerglobenewswire.com - April 18 at 9:00 AMQ1 2024 Earnings Forecast for Oncternal Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:ONCT)americanbankingnews.com - April 18 at 5:46 AMOppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)markets.businessinsider.com - April 17 at 2:17 PMOncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - April 17 at 2:14 AMOncternal Therapeutics (NASDAQ:ONCT) Price Target Cut to $28.00 by Analysts at HC Wainwrightamericanbankingnews.com - April 16 at 4:46 AMBuy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming Catalystsmarkets.businessinsider.com - April 15 at 7:00 PM5 Buy-Rated Stocks with Latest Insider Purchasesinsidermonkey.com - April 14 at 3:02 PMAIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USAfinance.yahoo.com - April 11 at 8:44 PMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Acquires $27,650.56 in Stockinsidertrades.com - April 11 at 6:48 AMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Robert James Wills Purchases 6,914 Sharesinsidertrades.com - April 2 at 4:26 AMOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancerglobenewswire.com - March 15 at 9:00 AMNorthland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)markets.businessinsider.com - March 13 at 1:49 PMOncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 10 at 3:41 PMQ4 2023 Oncternal Therapeutics Inc Earnings Callfinance.yahoo.com - March 8 at 11:39 AMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcriptmsn.com - March 8 at 11:39 AMOncternal Therapeutics's Earnings: A Previewbenzinga.com - March 8 at 6:38 AMONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023msn.com - March 7 at 10:45 PMOncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimateszacks.com - March 7 at 6:36 PMRecap: Oncternal Therapeutics Q4 Earningsbenzinga.com - March 7 at 5:45 PMOncternal Therapeutics: Q4 Earnings Snapshotwashingtonpost.com - March 7 at 5:45 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsChemomab TherapeuticsNASDAQ:CMMBChemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Hookipa PharmaNASDAQ:HOOKHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.ImmunomeNASDAQ:IMNMImmunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Oncternal TherapeuticsNASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.